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Blood–brain barrierMultiple sclerosis (MS) is a chronic neuroinﬂammatory disease characterized by immune cell inﬁltration of CNS,
blood–brain barrier (BBB) breakdown, localized myelin destruction, and progressive neuronal degeneration.
There exists a signiﬁcant need to identify novel therapeutic targets and strategies that effectively and safely dis-
rupt and even reverse disease pathophysiology. Signaling cascades initiated by semaphorin 4D (SEMA4D) induce
glial activation, neuronal process collapse, inhibit migration and differentiation of oligodendrocyte precursor
cells (OPCs), and disrupt endothelial tight junctions forming the BBB. To target SEMA4D, we generated a mono-
clonal antibody that recognizesmouse, rat,monkey and humanSEMA4Dwith high afﬁnity and blocks interaction
between SEMA4D and its cognate receptors. In vitro, anti-SEMA4D reverses the inhibitory effects of recombinant
SEMA4D onOPC survival and differentiation. In vivo, anti-SEMA4D signiﬁcantly attenuates experimental autoim-
mune encephalomyelitis in multiple rodent models by preserving BBB integrity and axonal myelination and can
be shown to promote migration of OPC to the site of lesions and improve myelin status following chemically-
induced demyelination. Our study underscores SEMA4D as a key factor in CNS disease and supports the further
development of antibody-based inhibition of SEMA4D as a novel therapeutic strategy forMS and other neurolog-
ic diseases with evidence of demyelination and/or compromise to the neurovascular unit.
© 2015 Vaccinex, Inc. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Multiple sclerosis (MS) is a neuroinﬂammatory disease triggered by
immune-mediated damage to neuronalmyelin sheaths in the brain, spi-
nal cord, and optic nerve. Demyelination resulting from periodic disease
relapses eventually leads to disrupted axonal signal transduction and
debilitating loss ofmotor function. Disease progression is difﬁcult to pre-
dict, as it depends on the subtype of the disease (relapsing–remitting,
secondary progressive, primary progressive, and progressive relapsing),
and is subject to individual variation in the severity of initial symptoms
and disease progression.
Although the agents and stimuli that initiate disease are presently
unknown, certain cellular and molecular processes relating to immune
system dysfunction, neuroinﬂammation, myelin damage and repair,
and blood–brain barrier (BBB) compromise have been shown to signif-e Avenue, Rochester, NY 14620,
er).
ect.com).
c. This is an open access article undeicantly contribute to the pathophysiology of MS. Disease-related lesions,
which are characterized by focal loss of myelin (Prineas, 1975), lympho-
cytic andmacrophage inﬁltrates, and activatedmicroglia and astrocytes,
are scattered throughout the CNS, but are found at highest frequencies
in the brainstem, optic nerve, spinal cord, and periventricular white
matter (Adams, 1977). Autoreactive T cells, especially those with Th1
and Th17 signatures, are believed to be primary drivers of monocyte re-
cruitment, oligodendrocyte toxicity, and myelin destruction (Pierson
et al., 2012). BBB compromise in MS patients is detectable not only in
focal lesions, but also in diffuse white matter abnormalities identiﬁed
by postmortemMRI, suggesting that dysfunction in BBBmay be a signif-
icant contributor to disease pathology (Vos et al., 2005).
While no cure for MS currently exists, therapeutics developed to
speciﬁcally target one or more of thesemechanisms have shown prom-
ise in reducing symptom severity and relapse frequencies. Many of the
currently FDA-approved medications are directed against the immune
component of MS via targeted immunosuppression to prevent
autoreactive T cells from entering the CNS and degrading myelin integ-
rity. Such strategies, while moderately effective, can have signiﬁcantr the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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2011; Miller et al., 2003; Berger, 2010).
There is a need to identify and rigorously test new strategies that
may intercede at multiple other points in MS pathogenesis and that
may effectively slow or even reverse progression of this debilitating dis-
ease. One such novel molecular target known to participate in several
processes affecting MS pathology, including inﬂammation, cellular mi-
gration, oligodendrocyte viability, and endothelial cell cytoarchitecture,
is semaphorin 4D (SEMA4D). Semaphorins comprise a family of soluble
and membrane-bound proteins that were originally deﬁned as axon-
guidance factors (reviewed by Giger et al., 2010). These proteins play
important roles in establishing precise connections between neurons
and their appropriate targets. Semaphorins and their receptors have
also been shown tohave important functions in other physiological pro-
cesses in the adult organism, including tissue repair, activation and mi-
gration of endothelial cells, survival and differentiation of neuronal and
oligodendrocyte precursor cells, tumor progression, and immune cell
regulation (Basile et al., 2007; Ch'ng and Kumanogoh, 2010; Giordano
et al., 2002; Giraudon et al., 2004; Suzuki et al., 2008). SEMA4D is a
150-kDa transmembrane protein expressed on the surface of T and B
cells, monocytes, platelets, and professional antigen-presenting cells,
such as dendritic cells (Kikutani and Kumanogoh, 2003; Suzuki et al.,
2008). Cellular activation can result in the generation of soluble
SEMA4D (sSEMA4D) by proteolytic cleavage of the extracellular portion
of transmembrane SEMA4D (Hall et al., 1996; Zhu et al., 2007). Levels of
sSEMA4D in normal mouse, rat, and human sera are similar, typically
ranging from 10 to 20 ng/mL (manuscript in preparation). Both
membrane-associated and soluble forms of SEMA4D are biologically
active.
Three cellular receptors have been identiﬁed for SEMA4D: Plexin-B1
(PLXNB1), Plexin-B2 (PLXNB2), and CD72. PLXNB1, the highest-afﬁnity
SEMA4D receptor (KD= 1 nM), is expressed in multiple tissues, includ-
ing dendritic cells, endothelial cells, and neural cells (Tamagnone et al.,
1999). SEMA4D engagement with PLXNB1 has been shown to induce
activation and migration of endothelial cells, and to promote migration
of tumor cells (Conrotto et al., 2005; Giordano et al., 2002). SEMA4D/
PLXNB1 signaling has also been reported to induce growth cone col-
lapse in neurons, apoptosis of neural precursor cells, and process exten-
sion collapse and apoptosis of oligodendrocytes (Giraudon et al., 2004;
Giraudon et al., 2005; Basile et al., 2007; Liang et al., 2004; Niederost
et al., 2002). PLXNB2 has an intermediate afﬁnity for SEMA4D and a re-
cent report indicates that PLXNB2 regulates migration of cortical neu-
rons independently of PLXNB1 (Azzarelli et al., 2014). CD72 is a
relatively low-afﬁnity (KD = 300 nM) SEMA4D receptor (Kumanogoh
et al., 2000) expressed on B cells, APCs and platelets. Agonistic anti-
CD72 antibodies exhibit many of the same effects as sSEMA4D, such as
enhancement of CD40-induced B cell responses and B cell shedding of
CD23. In addition, CD72 is thought to act as a negative regulator of B
cell responses by binding the tyrosinephosphatase SHP-1,which can re-
cruit many inhibitory receptors. An interaction between SEMA4D and
CD72 leads to the dissociation of SHP-1, and loss of this negative activa-
tion signal (Kumanogoh and Kikutani, 2001).
Inhibition of SEMA4D could have a profound impact on the course of
MSdue to itsmultiple functions in health and disease. First, given the role
of SEMA4D in inﬂammatory processes, inhibition of this semaphorin
could quell inﬂammation and secondary immune responses to CNS-
derived antigens (Okuno et al., 2010). Second, because SEMA4D has
been shown to be toxic to the oligodendrocyte lineage as well as
inhibiting migration and differentiation (Giraudon et al., 2004), blocking
its activity could reduce the loss of oligodendrocyte precursor cells (OPC)
and promote remyelination and repair in the setting of MS. Finally,
SEMA4D inhibition may preserve the integrity of the neurovascular
unit comprised of endothelial cells, pericytes and astrocytes by protecting
endothelial tight junctions (Basile et al., 2005; Yang et al., 2011), this
could serve to not only reduce immune and inﬂammatory cell inﬁltration
into the CNS but also to prevent activation of astrocytes andmicroglia. Toefﬁciently target SEMA4D,we generated amonoclonal antibody that rec-
ognizes SEMA4D from several species with high afﬁnity and blocks inter-
action between SEMA4Dand all of its known receptors, PLXNB1, PLXNB2,
and CD72. We employed a series of in vitro analyses and in vivo models
to show that antibody-based inhibition of SEMA4D is effective in blocking
the deleterious effects of this semaphorin on the oligodendrocyte lineage
and on BBB integrity. We demonstrate in vivo that antibody to SEMA4D
signiﬁcantly attenuates the severity of experimental autoimmune en-
cephalomyelitis (EAE) inmultiple rodentmodels, and promotes OPCmi-
gration to the site of lesions and repair following chemically induced
demyelination.
Materials and methods
Animals
Mice
All mouse EAE experimentswere carried out according to the guide-
lines of the National Institute of Health (NIH) and the University Com-
mittee on Animal Resources (UCAR) at the University of Rochester
(Rochester, NY) for the care and use of laboratory animals. Female
mice (C57BL/6 and SJL)weighing 25–35 gwere purchased from Taconic
and Charles River. All mice were housed at a standard temperature
(22 ± 1 °C) on a 12-h light/dark cycle and were allowed food and
water ad libitum. Rats: All rat EAE and lysolecithin-induced spinal cord
lesion experiments were carried out at Charles River-Discovery Re-
search Services (Kuopio, Finland) according to the National Institute of
Health (NIH) guidelines for the care and use of laboratory animals,
and approved by the National Animal Experiment Board, Finland.
Eight week-old female Dark Agouti (DA) rats weighing 120–170 g and
purchased from Charles River Laboratories, Germany, were used in a
subset of EAE experiments. Male Sprague–Dawley rats at the age of
8 weeks purchased from Charles River Laboratories, Germany, were
used for the lysolecithin lesion experiment. Animals were housed at a
standard temperature (22 ± 1 °C) on an 11/13-h light/dark cycle with
ad libitum access to food and water.
EAE models
Induction of active EAE in SJL mice
EAE was induced in 8 week-old female SJL/J mice (Charles River,
Wilmington,MA) by immunizingwith 0.1 mg PLP139–151 (Anaspec, Fre-
mont, CA) in 0.1 ml complete Freund's adjuvant (CFA; Hooke Laborato-
ries, Lawrence, MA), subcutaneously and divided between four sites on
the back of each mouse. Anti-SEMA4D antibody (MAb 67-2) or control
IgG antibody (MAb 2B8) was administered intraperitoneally (i.p.) on
day 7 andweekly thereafter (0.6 mg/injection; 18mice/group). Disease
progression was monitored by bodymass and clinical assessment using
a 6-point scoring system: (1) limp tail, (2) righting reﬂex is impaired,
(3) ataxia, (4) early paraparesis, (5) full paralysis, and (6) moribund/
death. Animals were euthanized when observed to attain score = 5.
Groupmean was calculated at each time point; a score of 5 was carried
over into later time points following death. Two-way ANOVA was
employed to analyze statistical signiﬁcance of treatment.
Adoptive transfer EAE in SJL mice
EAE was induced as described above in donor mice and, 10 days
later, CD4+ T cells were isolated from spleens and lymph nodes of the
donor EAE mice (negative selection, Miltenyi Biotec, Cambridge, MA)
and cultured at a concentration of 2 × 106 cells/ml in RPMI 1640 medi-
um supplemented with 10% FBS, 4 mM L-glutamine, 10 mM non-
essential amino acids, 1 mM sodium pyruvate, 100 U/ml penicillin/
streptomycin and 50 μM2-mercaptoethanol in the presence of irradiat-
ed (3400 rad) antigen presenting cells (APC) (APC:T cell ratio = 3:1).
To enrich for Th1 cell differentiation (Axtell et al., 2010; Jager et al.,
2009), cells were stimulated with 20 μg/ml PLP139–151, 20 μg/ml anti-
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murine IL-12 (R&D systems, Minneapolis, MN). After 72 h, cells were
collected, resuspended in media containing 20 μg/ml PLP139–151 and
20 U/ml (1.82 ng/ml) murine IL-2 (R&D systems, Minneapolis, MN)
and cultured on freshly irradiated splenocytes from naïve SJL/J mice
for an additional 5 d, followed by re-stimulation in the presence of
1 μg/ml anti-CD3 (Clone 145-2C11) and 0.5 μg/ml anti-CD28 (Clone
PV-1) for 48 h. Th1 cells were collected and 2 × 106 cells were injected
i.p. into naïve SJL/J donors. To assess population purity, the remaining
Th1 cells were stimulated with 50 ng/ml PMA (Sigma, St Louis, MO)
and 1 μM ionomycin (Sigma, St Louis, MO) for 4.5 h and supernatants
were analyzed by ELISA for the presence of Th1-speciﬁc cytokine, IFNγ
(data not shown). Anti-SEMA4D antibody (MAb 67-2) or control IgG
antibody (MAb 2B8) was administered i.p. on the same day as adoptive
transfer and twiceweekly thereafter (0.6 mg/injection; 12mice/group).
The treatment with recombinant murine IFN-β (PBL Interferon Source,
Piscataway, NJ) consisted of i.p. injections of 1000 U three times a
week starting on the day of the adoptive transfer. Disease progression
was monitored as described above.
Induction of EAE in C57BL/6 mice
EAEwas induced in naïve ~8week-old (18–22 g)male C57BL/6mice
by immunization with emulsion containing 0.15 mg MOG35–55 in CFA
enriched with Mycobacterium tuberculosis (4 + 1 = 5 mg/mL CFA) in
a volume of 0.2 ml/mouse, injected subcutaneously into the ﬂank.
Anti-SEMA4D antibody (MAb 67-2) or control IgG antibody (MAb
2B8) was administered i.p. on day 7 and twice weekly thereafter
(0.6 mg/injection; 14 mice/group). Disease progression was monitored
by body mass and clinical assessment using a 6-point scoring system:
(1) limp tail, (2) righting reﬂex is impaired, (3) ataxia, (4) early
paraparesis, (5) full paralysis, and (6) moribund/death. Group mean
was calculated at each time point; a score of 6 was carried over into
later time points following death. Two-way ANOVA was employed to
analyze statistical signiﬁcance of treatment.
Induction of EAE in DA rats
EAE was induced in female Dark Agouti (DA) rats (Charles River,
Germany) by administration of 100 μL inoculum intradermally at the
base of the tail. The inoculum consisted of 20 μg of recombinant
MOG1–125 (Anaspec, Australia) in PBS emulsiﬁed with incomplete
Freund's adjuvant (IFA) (1:1) containing 200 μg of heat-inactivated
M. tuberculosis (strain H 37 RA; Difco, Detroit, MI). Anti-SEMA4D anti-
body (MAb 67-2) or control IgG antibody (MAb 2B8)was intravenously
administered at 15 mg/kg on days 3, 7, 10, 14, 21 and 28 (30 rats/
group). Disease progression was monitored by body mass and clinical
assessment using a 5-point scoring system: (1) tail paralysis; (2) partial
weakness in one limb (usually hind limb); (2.5) complete paralysis in
one limb — (no movement preserved in affected limb); (3) partial
weakness in both hind limbs; (3.5) complete paralysis in both hind-
limbs (hind-limbs dragged along), or partial weakness in limbs on one
side of the body (hemiparesis); (4) partial weakness in all four limbs
or complete paralysis on one side of the body (hemiplegia); and
(5) complete paralysis of all four limbs (tetraplegia),moribund. Animals
were euthanized when observed to attain score = 5. Group mean was
calculated at each time point; a score of 5 was carried over into later
timepoints following death. Two-way ANOVAwas employed to analyze
statistical signiﬁcance of treatment.
High-resolution frequency analysis of cytokine-secretingmouse splenocytes
by enzyme-linked immunosorbent spot (ELISPOT) assay
Mouse IFNγ and interleukin-17a ELISPOT “READY-SET-GO!” Kits
from eBioscience (San Diego, CA) were used according to the manufac-
turer’s protocol. Mononuclear cells from spleens of mice immunized
with PLP139–151 peptide were recall-activated in triplicate 96-well U-
bottom Multi-screen ﬁlter plates with Immobilon-P membranes(Millipore, Billerica, MA). 96-Well polyvinylidene diﬂuoride (PVDF)
membrane ELISPOT plates were pre-coated with the respective anti-
cytokine capture antibodies and mouse splenocytes were incubated at
a cell density of 2.5 × 106 cells/ml with PLP139–151 peptide at 25 μg/ml
for 20 h at 37 °C. Cells in control wells were incubated with medium
alone (RPMI, 10% FBS, non-essential amino acids, 15 mM HEPES and
15 μg/ml gentamicin) in the absence of recall peptide. Cells were
washed off and the ELISPOT SET protocol followed to perform the
assay. Spots were developed to the optimal intensity, and air-dried
plates were scanned and analyzed by Cellular Technology Ltd. (Shaker
Heights, OH).
CFSE splenocyte proliferation assay
CellTrace CFSE Cell ProliferationKit (Invitrogen, Grand Island, NY)was
used according to the manufacturer's instructions. Brieﬂy, mononuclear
cells (MNCs) isolated from spleens of treated mice were resuspended to
a ﬁnal concentration of 2 × 06 cells/ml in PBS, 1% BSA. Cells were stained
with 10 μMCFSE dye for 15min at 37 °Cwith occasionalmixing. Staining
was then quenched by the addition of 5 volumes of ice cold PBS/BSA and
subsequent washing of the cells. Cells were resuspended to a ﬁnal con-
centration of 2 × 06 cells/ml in complete DMEM (DMEM, 10%FBS, pen-
strep, L-Glutamine, nonessential amino acids, HEPES, 50 μM 2-ME). Cells
were restimulated in culture with PLP139–151 (50, 500, or 5000 ng/ml),
PMA/ionomycin cell stimulation cocktail (eBioscience, San Diego, CA),
or media alone. All culture conditions were set up in triplicate in 96-
well U bottom plates. On day 4, triplicate wells were pooled and cells
were harvested, washed with PBS, 1% BSA and then stained with mouse
anti-CD3-APC clone 145-2C11 (eBioscience, San Diego, CA). Samples
were gated on CD3+ cell population and 20,000 events acquired using
FACSCanto™II ﬂow cytometer. FlowJo version 7.6 was used for data anal-
ysis of CFSE ﬂuorescence.
Cytometric bead array (CBA) cytokine analysis
MNCs were isolated from brains and spinal cords of treated animals
following perfusion with PBS/heparin. Tissues were separated into
small pieces using a scalpel and syringe plunger and the tissue homog-
enate was pressed through a 70-μm cell strainer and washed with ice-
cold PBS. Samples were pooled within each treatment group and
MNCs isolated by a 30%:70% Percoll (Sigma, St Louis, MO) gradient. Iso-
lated cells were then washed and stimulated for 4 days using culture
conditions for cell proliferation. On day 4, culture supernatants were
collected and stored at -80 °C for subsequent analysis. Fifty microliters
of each sample was analyzed for IL-2, IL-4, IL-6, IL-10, IL-17, TNFα and
IFNγ using BD's mouse TH1/TH2/TH17 CBA kit and a FACSCanto™II
ﬂow cytometer. CBA sample analysis was completed following kit in-
structions. Statistical analysis software GraphPad Prism 5 was used for
graphing of standard curves and extrapolation of data.
Immunohistochemistry formouse B cells, T cells, andmacrophage/microglia
For B cells, 5-μm PFA-ﬁxed, parafﬁn-embedded sections were
deparafﬁnized using Xylenes baths and rehydrated with graded eth-
anol baths. Epitope retrieval was carried out by a 20-min boil with
Target Retrieval Solution (Dako, Carpinteria, CA) followed by 30-
min cooling. Slides were washed twice with PBS containing 0.05%
Tween-20 (TPBS), then endogenous peroxidases were inactivated
with a 10-min block with Dual Enzyme Block (Dako, Carpinteria,
CA). Slides were washed with TPBS twice, and nonspeciﬁc binding
was blocked by a 20-min incubation with 2.5% normal goat serum
in TPBS. Following a single TPBS wash, slides were incubated for
60 min with rat anti-CD45R (R&D systems, Minneapolis, MN)
(clone RA3-6B2) at 0.3 μg/ml in TPBS, followed by 2 TPBS washes.
Slides were then incubated for 10 min with Polink-2 rat enhancer
(Golden Bridge, Mukilteo, WA) followed by 10 min with Polink-2
257E.S. Smith et al. / Neurobiology of Disease 73 (2015) 254–268HRP Polymer, washing 3× with TPBS between steps. This was
followed by a 5-min DAB+ incubation (Dako, Carpinteria, CA). Sec-
tions were counterstained with Harris hematoxylin, destained,
blued with tap water, dehydrated, and non-aqueous mounted with
Permount. For detection of macrophage/microglia, staining was per-
formed as above, using rat anti-F4/80 (Abcam, Cambridge, MA)
(clone A3-1) at 0.5 μg/ml. For T cell detection, staining was per-
formed as above, with the following changes: primary antibody
was rabbit anti-CD3 (Abcam, Cambridge, MA) at 2 μg/ml. In addition,
Polink enhancer and Polink HRP-Polymer incubations were replaced by
one 20-min incubation with Envision + anti-rabbit HRP polymer
(Dako, Carpinteria, CA). Slides were imaged at 20× magniﬁcation
using a Retiga QICAM-12 bit camera coupled to an Olympus Ix50
microscope.
Evaluation of anti-SEMA4D in the rat inﬂuenza viral clearance model
Anti-SEMA4D was evaluated for immune suppression in an inﬂuen-
za host resistance model in Sprague Dawley, CD male and female rats
by measuring viral clearance in lung homogenates. Anti-SEMA4D
(VX15/MAb 2503) was delivered at 5 weekly intravenous doses of 10,
100, or 200 mg/kg prior to virus infection and 3 weekly doses subse-
quent to infection (25males and 25 females per group). A vehicle control
group was dosed similarly to serve as a negative control and dexameth-
asonewas administered at 2 mg/kg/day to a separate cohort to serve as a
positive control for immune suppression. After 5 doses of anti-SEMA4D
rats were infected intranasally with a rat-adapted inﬂuenza virus (ap-
proximately 2 × 105 plaque forming units) to determine whether anti-
SEMA4D inhibited the rat's ability to clear virus. For the infection, ani-
mals were anesthetized with isoﬂurane and infected intranasally with
an H3N2 rat-adapted inﬂuenza virus (RAIV) as a 1:100 dilution of the
stock virus (approximately 2 × 105 plaque forming units) in a volume
of 200 μl. Animals that sneezed or snorted the dose immediately after
the intranasal administration received a second 100 μl intranasal dose
of the infection suspension as soon as possible after the ﬁrst dose was
attempted. On days 1, 2, 4, 8, and 21 post-infection, animals were eutha-
nized and infectious virus titers were determined. Whole-lung homoge-
nates were prepared at 10% w/v, split into aliquots, and stored frozen at
−70 °C. Dilutions of the animals' whole lung homogenate (each per-
formed in duplicate) were added to monolayers of Madin Darby Canine
Kidney (MDCK) cells and coveredwith an agarose overlay. Following in-
cubation for 36–48 h to allow plaque development, the cell monolayers
were ﬁxed with buffered formalin and stained with crystal violet. Viral
plaques were counted visually to determine infectious virus titer and
expressed as log plaque-forming units (PFU) per gram of lung tissue.
DIV–BBB model
A dynamic in vitro blood–brain-barrier model (DIV–BBB) was used
as previously described (Cucullo et al., 2011). Brieﬂy, a bundle of hollow
ﬁbers was suspended inside a sealed chamber and ﬂow of cell culture
medium was maintained throughout the experiment. Human cerebral
endothelial cells were cultured on the luminal (vascular) side of these
ﬁbers and human astrocytes were cultured on the outer (CNS) surface.
Ports positioned on both the luminal and the abluminal sides allowed
access to both compartments. Once a tight barrierwas established as de-
termined by transendothelial electrical resistance (TEER), usually after
14 days, recombinant SEMA4Dwas added to the luminal side at various
concentrations followed by either anti-SEMA4D (VX15/2503) or control
IgG (MAb 2955) and the integrity of the barrier was continually moni-
tored by measuring the transendothelial electrical resistance (TEER).
Primary mouse brain microvascular endothelial culture analyses
C57BL/6 mouse brain microvascular endothelial cells (mBMVECs;
CellBiologics, Chicago, IL) were seeded onto gelatin-coated wells andgrown to conﬂuence for 5 days to allow for tight junction formation,
withmedia changes on days 2 and4. Cellswere then treated in triplicate
wells with media alone, 100 ng/ml recombinant TNFα (Millipore,
Billerica, MA), or recombinant mouse SEMA4D for 6 or 12 h. For West-
ern blotting, the wells were washed with cold PBS and scraped into
200 μl of ice-cold lysis buffer (50 mmol/L Tris pH 7.5, 4 mmol/L EDTA,
10% ethylene glycol, 250 mmol/L sucrose, 1 mmol/L dithiothreitol, 1×
protease inhibitor cocktail (Roche, Indianapolis, IN), as previously de-
scribed (Errede et al., 2012). Lysates were sonicated on ice for 15 s,
and then frozen at−20 °C. Prior to gel loading, samples were thawed
on ice and pelleted by centrifugation at 13,000 RPM for 10 min. To
65 μl lysate supernatant, 25 μl NuPAGE buffer and 10 μl reducing agent
were added, then the sampleswere heated at 70 °C for 5min. Each sam-
ple (15 μl) was loaded on a NuPAGE gel and run at 150 V for 1.5 h, then
transferred to PVDF for 7 min using an iBlot system (Invitrogen, Grand
Island, NY). Blots were blocked with 5% milk in PBS/0.05% Tween-20
overnight at 4 °C, then probed for Claudin-5 (Abcam, Cambridge, MA)
or β-actin (Cell Signaling Technology, Danvers, MA) for 1 h at RT,
followed by HRP-labeled goat anti-rabbit IgG H + L (Jackson
ImmunoResearch, West Grove, PA) for 30 min at RT. Signal was devel-
oped using ECL Prime (GE Healthcare Life Science, Pittsburgh, PA) and
imaged using a FluorChem HD2 imaging system (Alpha Innotech, Jo-
hannesburg, SA). Densitometry was calculated using NIH ImageJ. For
immunoﬂuorescence, cells were washed with PBS and ﬁxed for
20 min with 4% paraformaldehyde in PBS with 0.05% Tween-20
(TPBS). Cells were permeabilized for 30 min with 0.05% Saponin
(Sigma, St. Louis, MO) in TPBS, washed, and subsequently blocked
with 2.5% normal goat serum (Jackson ImmunoResearch, West Grove,
PA). Cells were incubated with 10 μg/ml mouse anti-Claudin-5
(Invitrogen, Grand Island, NY) for 60 min, washed, then incubated
with a 1:500 dilution of donkey anti-mouse secondary (Invitrogen,
Grand Island, NY) and washed. Slides were then labeled for 10 min
with 500 ng/ml DAPI, washed, andmounted using ProlongGoldmount-
ing medium (Invitrogen, Grand Island, NY).
Fibrinogen detection
For detection of ﬁbrinogen, a rabbit anti-ﬁbrinogen antibody (Dako,
Carpinteria, CA)was used. Brieﬂy, frozen sectionswere allowed to reach
room temperature for 20 min and hydrated with PBS for 1 min. Slides
were washed with PBS and blocked for 30 min with PBS containing
10% goat serum, 0.3% Triton X-100. Primary antibodies (anti-ﬁbrinogen
at 1:1000) were added and incubated overnight at 4 °C. Slides were
washed rigorouslywith PBS containing 0.3% Triton X-100, then incubat-
ed 1 h at RT with Alexa-488 goat anti-rabbit (Invitrogen, Grand Island,
NY) diluted at 1:100 in blocking buffer. Slides were washed with PBS
containing 0.3% Triton X-100 and mounted with DAPI Fluoromount-G
(Southern Biotech, Birmingham, AL).
Detection of therapeutic antibody in the brain via ﬂow cytometry
SJL mice induced with PLP139–151 peptide and CFA were injected
with 600 μg of VX15/2503 or control IgG. Two days later, brains were
harvested from perfused mice and processed for mononuclear cells
using Percoll gradient (56). A naïve SJLmousewas included as a control.
For each condition, staining was done to determine the expression
(measured as percent saturation) of SEMA4D on CD3+ T lymphocytes
using 3 sample tubes processed in parallel. The ﬁrst tube served as a
negative isotype control and was incubated with mouse anti-chicken
IgG-biotin (Southern Biotech, Birmingham, AL). The second tube was
the experimental sample and was incubated with mouse anti-human
IgG4-biotin (Southern Biotech, Birmingham, AL). This sample indicated
the amount of VX15/2503 bound to surface SEMA4D on the cells. The
third tube was a positive control used to measure the maximum
amount of possible VX15/2503 on the surface of the cells. This tube
was incubated with excess VX15/2503 followed by mouse anti-human
258 E.S. Smith et al. / Neurobiology of Disease 73 (2015) 254–268IgG4-biotin. All three tubes received FITC-conjugated rat anti-mouse
CD3 antibody (clone 17A2) (BD, San Jose, CA) and Streptavidin-APC
(Southern Biotech, Birmingham, AL), and 5000 gated CD3+ events
were acquired on a BD FACSCanto II™ cytometer. The geometric mean
ﬂuorescence intensity (GMFI) was determined on the T cell population.
Percent saturation was calculated with the following equation: ((GMFI
Tube 2− GMFI Tube 1) / GMFI Tube 3− GMFI Tube 1)) ∗ 100. Greater
levels of bound VX15/2503 result in a higher GMFI for Tube 2 and higher
percent saturation.Detection of therapeutic antibody in the brain via IHC
For therapeutic antibody detection, 5-μm paraformaldehyde
(PFA)-ﬁxed, parafﬁn-embedded sections were deparafﬁnized using
Xylene baths and rehydrated with graded ethanol baths. Epitope re-
trieval was carried out by a 20-min boil with Target Retrieval Solu-
tion (Dako, Carpinteria, CA) followed by a 30-min cooling period.
Slides were washed twice with PBS containing 0.05% Tween-20
(TPBS), then endogenous peroxidases were inactivated with a
10 min block with Dual Enzyme Block (Dako, Carpinteria, CA). Slides
were washed with TPBS twice, and nonspeciﬁc binding was blocked
via a 20-min incubation with 2.5% normal horse serum in TPBS. Fol-
lowing a single TPBS wash, therapeutic antibody (MAb 2B8 or MAb
67-2) was detected with a 60-min incubation with a rat-adsorbed
anti-mouse HRP polymer kit (Vector, Burlingame, CA), followed by
two TPBS washes and a 5-min DAB+ incubation (Dako, Carpinteria,
CA). Sections were then counterstained with Harris hematoxylin,
destained, blued with tap water, dehydrated, and non-aqueous
mounted with Permount.Primary rat oligodendrocyte cultures
Oligodendrocyte precursor cells (OPC) were isolated from mixed
neuronal cultures obtained from dissociated spinal cord or cortices of
P2 rat pups. Brieﬂy, spinal cord or brain cortices were ﬁnely chopped
and dissociated using a neural tissue dissociation kit (Miltenyi, Cam-
bridge, MA). Dissociated cells were seeded on poly-L-lysine (PLL)-coat-
ed T-75 ﬂasks and cultured in DMEM containing 10% FBS/Pen–Strep/
gentamicin at 50 mg/ml for 10–14 days. OPC were harvested by shak-
ing the mixed neural culture ﬂasks at 130 rpm overnight at 37 °C. This
method routinely yielded 95% pure bipolar A2B5-positive OPC as con-
ﬁrmed by ICC. These OPCs were then cultured for 5–7 days in OPCM
(Neurobasal medium (Invitrogen, Grand Island, NY) + B27 serum free
supplement (Invitrogen, Grand Island, NY) + 20 ng/ml of human
bFGF (Peprotech, Rocky Hill, NJ) + human PDGF (Peprotech, Rocky
Hill, NJ) in PLL-coated T-25 dishes.OPC collapse assay
OPC grown in OPCM were harvested by trypsinization and seeded
for a collapse assay on PLL-coated 48-well plates at 1.2 × 104 cells per
well. They were cultured in OPCDM (Neurobasal medium + B27 +
CTNF (ciliary neurotrophic factor from rat (Sigma, St Loius, MO)
(10 ng/ml) + 15 nM Triiodo-L-thyronine (Sigma, St Louis, MO) for
4 days and then treated with either control protein or recombinant
his-tagged SEMA4D (rSEMA4D-His) at 50 μg/ml +/− anti SEMA4D an-
tibody (VX15/2503) at 500 μg/ml for 30min. Treatmentwas terminated
by ﬁxing cells in 4% PFA added directly to treatment wells. Cytoskeletal
changes were visualized by staining treated cells with Phalloidin-
Alexa488 (Invitrogen, Grand Island, NY) at 1:40 for 30 min post-
permeabilization with 0.1% Triton X-100. Actin reorganization was im-
aged at 20× magniﬁcation using an Exi Aqua camera coupled to an
Olympus Ix50 microscope.OPC apoptosis and differentiation assay
OPC grown in OPCMwere harvested by trypsinization and seeded
at 1.5 × 104 cells per well onto 48-well plates coated with PLL (10 μg/
ml) + BSA (50 μg/ml), PLL (10 μg/ml) + SEMA4D (50 μg/ml) or PLL
(10 μg/ml) + SEMA4D (50 mg/ml) + anti-SEMA4D (VX15/2503;
250 μg/ml) for 2 h at 22 °C. Cells were cultured in the presence of
OPCDM for 4 days for the apoptosis assay or 8 days for the differen-
tiation assay. On day 4 and day 8, cells were ﬁxed with 4% PFA for
20 min and transferred to PBS. The apoptotic cell fraction on day 4
was determined by immunocytochemical staining for activated
caspase-3 (Abcam, Cambridge, MA) in the GalCer-positive fraction
of plated cells. Differentiation on day 8 was assayed by determining
the expression of myelin basic protein (MBP; clone 7D2; Abcam,
Cambridge, MA) by immunocytochemistry. Activated caspase 3-
and MBP-positive cells were imaged at 20× magniﬁcation using an
EXi Aqua camera coupled to an Olympus Ix50 microscope. A mini-
mum of 1000 cells/well and 6000 cells/treatment were imaged for
each condition and % positive cells quantiﬁed using Image-Pro Plus
software (MediaCybernetics, Rockville, MD). Data from 6 wells/
treatment group were averaged and subjected to statistical analysis
(ANOVA) to assess signiﬁcance.
Lysolecithin lesion model
Focal demyelination in spinal cord was induced by stereotactic
infusion of 1% lysophosphatidylcholine (LPC) into a deﬁned level of the
rat spinal cord. Brieﬂy, rats were anesthetized with isoﬂurane and a
laminectomy was performed at T9–T10 level. A volume of 2 μl
of 1% LPC (Sigma-Aldrich, St. Louis, MO) was injected into the cord at
1 μl/min. Following wound closure, the rats recovered in homeothermic
cages before being returned to home cage. At 2 days post-injury, intrathe-
cal cannulationwas performed. An incision of the ligamentum ﬂavumbe-
tween T7 and T8 was made followed by a partial T8 laminectomy. A rat
intrathecal catheter (Alzet) ﬁlled with either MAb 67-2 or MAb 2B8 solu-
tion (7.5 μg/μl) and attached to Alzetminipump (Model #2002with ﬂow
rate of 0.5 μl/h) containing the corresponding dosing solution was then
inserted into the subarachnoid space, and the tip of the catheter was ad-
vanced caudally to within 1 mm of the injury epicenter. Following im-
plantation and wound closure, rats recovered in homeothermic cages
before being returned to home cages. A monoclonal antibody dose of
90 μg/day was infused into the intrathecal space via the Alzet pump at
the rate of 0.5 μl/h until end-point day 14 post-LPC infusion. Three rats
from LPC-lesioned groups and 3 rats from the sham groupwere perfused
with 4% paraformaldehyde for ex vivo MRI and immunohistochemical
analyses. The remaining 9 rats from LPC-lesioned groups and 3 rats
from the sham group were perfused with 4% glutaraldehyde for ex vivo
MRI and toluidine blue histochemistry
Ex vivo MRI analyses of LPC-lesioned spinal cords
MRI was performed on ﬁxed and dissected spinal columns in a hori-
zontal 7 T magnet with bore size 160 mm equipped with a gradient set
capable of maximum gradient strength 750 mT/m and interfaced to a
Bruker AVANCE III console (Bruker BioSpin GmbH, Ettlingen, Germany).
A volume coil (Bruker Biospin GmbH, Ettlingen, Germany) was used for
transmission and surface phased array coil for receiving (Rapid Biomed-
ical GmbH, Rimpar, Germany). Prior to imaging, sampleswere placed in a
tube ﬁlled with perﬂuoro polyether to prevent signal from the solution
and ﬁxed to a holder in a standard orientation relative to the magnet
bore. For determining the lesion volumes, samples were scanned using
a FLASH sequence with the following parameters: Echo Time/Repetition
Time (TR/TE) = 1300/3.5 ms, ﬂip angle = 90°, image matrix size =
160 × 160, slice thickness = 0.5 mm, number of slices = 40, ﬁeld of
view (FOV) = 9.6 × 9.6 mm2 and 24 signal averages per k-space line.
Imaging resolution was 60 × 60 × 500 μm3 and imaging time was for
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software.
Toluidine blue staining and TEM analysis
Naïve rats, LPC-lesioned rats, and rats with EAE and treated with
control IgG or anti-SEMA4Dwere perfused transcardially with heparin-
ized (2.5 IU/ml) phosphate buffer (PB) (0.1M sodiumphosphate buffer,
pH 7.2) followed by perfusionwith 4% glutaraldehyde diluted in PB. Fol-
lowing perfusion the top of the skull was removed to allow for adequate
ﬁxation of the brain. Both the head and spinal columnwere placed in 4%
glutaraldehyde in PB. Five cross sections were cut from each cord,
starting at L1 and cutting every 2 mm in a distal direction. Each cross
sectionwaspost-ﬁxed in osmium tetroxide, processed through a graded
series of alcohols, inﬁltrated into liquid epoxy resin (Epon/Araldite),
embedded into molds, and polymerized at 70 °C. Five 1-μm sections
were cut from each cross section using an ultramicrotome with a glass
knife, which were then stained with Toluidine Blue. Sections were
scanned with an Objective Imaging Turboscan system on an Olympus
IX50with a 1.35NA60×oil objective. To perform a uniformquantitation
of all samples, the dorsal column was selected as the area for quantita-
tion in each section. This region has well-deﬁned borders and is
enriched for myelinated axons, making it a frequent site of demyelinat-
ing events. Additionally, the lumbar region (L1 speciﬁcally) was select-
ed based on previous observations that this area of the cord routinely
contains lesion loads that correlate with disease severity. For quantita-
tion, the blue channel was extracted from each image, and its histogram
equalized using Adobe Photoshop. ImagePro Plus was then used to
apply a HiGaussﬁlter to accentuatemyelin edges, and the area occupied
bymyelin stain was then calculated as a percentage for the region of in-
terest (dorsal column). For TEM, the optic nerve and the dorsal column
of the spinal cord were selected for further analysis. Thin sections were
cut and placed onto grids. Images were captured using a Hitachi 7650
Analytical TEM with an Erlangshen 11-megapixel digital camera and
Gatan software.
Statistical analyses
Statistical analysis was performed bymeans of Student 's t-test or
2-way analysis of variance (ANOVA) followed by the Bonferroni
post-test, when applicable, using GraphPad Prism (GraphPad Soft-
ware, San Diego, CA).
Results
Antibody to SEMA4D improves clinical scores in multiple EAE models
Because of the potential role(s) of SEMA4D in cellular processes that
contribute to pathogenesis in neuroinﬂammatory and neurodegenera-
tive diseases and because sera from individualswithMS contain on aver-
age 2.6 times higher soluble SEMA4D than sera from unaffected
individuals (Supplementary Fig. S1), we generated a high afﬁnity anti-
body to efﬁciently block the activity of this semaphorin family member
in vivo. Using SEMA4D knockout mice, standard immunization and hy-
bridoma methods were employed to select a panel of murine anti-
human SEMA4D-speciﬁc antibodies. Many of these antibodies were
found to cross-react with human, primate, rat and mouse SEMA4D. An-
tibodyproduced by hybridoma clone 67-2 (MAb67-2) exhibited high af-
ﬁnity by surface plasmon resonance (SPR) for bothmurine (KD= 1 nM)
and human recombinant SEMA4D (KD = 5.7 nM). Flow cytometry-
based functional studies demonstrated that MAb 67-2 (IgG1) blocked
the binding of SEMA4D to PLXNB1, PLXNB2, and CD72 expressed on
the surface of transfected cells (data not shown). MAb 67-2 served as
the progenitor antibody for the generation of a humanized anti-
SEMA4D IgG4 antibody (VX15/2503). Neither MAb 67-2 nor VX15/2503 are cytotoxic in vitro or deplete SEMA4D-positive lymphocytes
in vivo (data not shown).
To examine the contribution of SEMA4D to mechanisms underlying
neuroinﬂammatory disease, MAb 67-2was tested in 4 rodentmodels of
experimental autoimmuneencephalomyelitis (EAE): 1) SJLmice immu-
nized with PLP peptide 139-151, 2) adoptive transfer into SJL mice of
PLP-peptide primed T cells enriched for Th1 in vitro, 3) C57BL/6 mice
immunized with myelin oligodendrocyte glycoprotein (MOG)-peptide
35-55, and 4) Dark Agouti (DA) rat immunized with MOG1–125..
SJL mice develop a relapsing–remitting experimental autoimmune
encephalomyelitis (RR-EAE) in response to immunization with a pep-
tide epitope of proteolipid protein (PLP139–151) in Complete Freund’s
Adjuvant (CFA). This model is characterized by a moderate to severe
acute paralytic phase followed by remission and subsequent relapses.
Treatment of SJL mice with anti-SEMA4D antibody (MAb 67-2) starting
7 to 10 days after PLP139–151 immunization reduced the severity of dis-
ease by approximately 50% as compared to mice receiving isotype con-
trol antibody (MAb2B8) (Fig. 1A). These results conﬁrmdata previously
reported by Kumanogoh and colleagues, who described SEMA4D-null
mice as exhibiting less severe clinical signs of EAE than their wild-type
counterparts (Kumanogoh et al., 2002) and subsequently demonstrated
amelioration of EAE in SJLmice by systemic treatmentwith an indepen-
dent anti-SEMA4D antibody (Okuno et al., 2010).
In addition to active immunizationwithmyelin peptides, EAE can be
induced in SJL mice by adoptive transfer of pre-activated PLP peptide-
speciﬁc, Th1-polarized T cells (Ishida et al., 2003). In these experiments,
splenic CD4+ T cells of SJL donor mice immunized with PLP139–151/CFA
emulsion were isolated and re-stimulated in vitro with PLP139–151 pep-
tide and IL-12 in the presence of anti-IL-4 antibody to enrich for Th1
cells prior to transfer into recipient SJL mice. Administration of anti-
SEMA4D antibody starting on day 10 post-adoptive transfer reduced
the severity of Th1 cell-mediated EAE relative to mice treated with con-
trol IgG. Disease ameliorationwas comparable to that achieved by treat-
ment with recombinantmurine interferon-β (IFN-β; Fig. 1B). Results in
this model demonstrate that interference with EAE progression is not
simply due to blocking T cell activation.
In contrast to the relapsing–remitting disease induced in SJL mice,
EAE induced in C57BL/6 mice by subcutaneous injections of MOG35–55
peptide emulsiﬁed in CFA induces a chronic course of disease. Treat-
ment with anti-SEMA4D dramatically reduced the group mean score
(GMS) of clinical signs of EAE (Fig. 1C). Notably, these experiments
were performed in the absence of pertussis toxin which is often
employed to potentiate disease in this murine strain. Among other pos-
sible pathogenic effects, pertussis toxin compromises the blood–brain
barrier (Bruckener et al., 2003) by mechanisms which are distinct
from those mediated by inﬂammatory cells and which appear not to
be readily reversed by anti-SEMA4D antibody. As shown in Fig. 1C,
even in the absence of pertussis toxin, relatively high clinical scores
were induced in control mice.
Immunization of DA rats with whole MOG protein in CFA induces
EAE with an acute phase of disease followed by an extended period of
chronic neurological deﬁcit and pathology (Mi et al., 2007). Unlike
other peptide-based EAE models, anti-MOG antibodies, as well as T
cells, are believed to play a key role in the disease that develops in this
rat model. Treatment of these animals with anti-SEMA4D resulted in a
32% attenuation in disease severity (Fig. 1D).
Administration of anti-SEMA4D antibody does not result
in immunosuppression
Within the normal CNS, SEMA4D is robustly expressed on Nkx2.2-
positive oligodendrocyte precursors, while its major receptors, plexin-
B1 and CD72, are expressed on multiple cell types and especially prom-
inent on astrocytes which are intimately associated with neurons and
microglia (Supplementary Fig. S2). In the setting of EAE, SEMA4D ex-
pression can also be readily detected on inﬁltrating macrophages and
Fig. 1.Anti-SEMA4D antibody treatment signiﬁcantly improves clinical scores inmultiple rodentmodels of EAE. (A) SJLmicewere immunizedwithmyelin proteolipid protein amino acids 139-
151 (PLP139–151) in Complete Freund's Adjuvant (CFA). Starting on day 7, mice were injected 1× perweekwith control IgG (MAb 2B8) or anti-SEMA4D (MAb 67-2) antibody (N= 18/group).
Standard EAE clinical scoringwasperformedover a 50-dayperiod. (B) For the Th1 adoptive transfer EAEmodel, SJL donormicewere immunizedwithPLP139-151 inCFA. Tendays later CD4+T
cellswere isolated fromspleens and lymphnodes andwere re-stimulatedwith peptide, IL-12 and anti-IL-4MAb. After culture and re-stimulation, T cellswere transferred into recipient SJLmice.
Starting at day 0 post-T cell transfer, mice were injected i.p. weekly with eitherMAb 2B8 orMAb 67-2, or 3×/week with recombinant murine interferon-beta (IFN-β; N= 12/group), and EAE
clinical scores were recorded over a 24-day period. (C) Male C57BL/6 mice were immunized with MOG35–55 peptide in CFA (N= 8–9/group). Mice received MAb 2B8 or MAb 67-2 2X/week
beginning on day 4 post-MOG immunization, and EAE clinical scores were recorded over a 41-day period. (D) Dark Agouti (DA) rats (N = 30/group) were immunized with MOG1–125 in In-
complete Freund’s Adjuvant (IFA) containing 200 μg of heat-inactivatedMycobacterium tuberculosis (strain H 37 RA). Starting on day 3 post-MOG immunization, rats received MAb 2B8 or
MAb 67-2 2×/week up to peak disease (approximately day 14), then 1×/week thereafter. EAE clinical scores were recorded over a 35-day period. Error bars indicate standard error of the
mean (SEM). Statistical signiﬁcance was determined by 2-way ANOVA where “*”= p b 0.05, “**”= p b 0.01, “***”= p b 0.005, and “****”=p b 0.0001.
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and to a lesser extent on other immune cells, including B cells, NK cells,
and APC and has been shown to play a role in the control of immune cell
activation and migration (Delaire et al., 2001; Ishida et al., 2003).
Given the purported role of SEMA4D in immune responses, we inves-
tigated whether antibody-mediated neutralization of this semaphorin is
immunosuppressive. The immune response proﬁles engendered against
an EAE-inducing peptide were assessed in the presence and absence of
anti-SEMA4D antibody treatment in vivo. EAE was actively induced in
SJL mice by PLP139–151/CFA immunization, and on days 6 and 10 post-
immunization mice received control IgG or anti-SEMA4D antibody. At
study end, spleens, brains, and spinal cords were processed for ELISPOT,
T cell proliferation, and cytokine assays. ELISPOT analysis of PLP139–151
re-stimulated mononuclear cells from the spleens of control IgG or
anti-SEMA4D treated EAE mice revealed no signiﬁcant differences in
peptide-speciﬁc IL-17a or IFNγ release between the groups (Supplemen-
tary Fig. S3A). T cell proliferation assays indicated a signiﬁcant peptide-
speciﬁc proliferative response was detected with no differences in T cell
proliferation between samples obtained from control IgG or anti-
SEMA4D treated EAE mice (Supplementary Fig. S3B). Mononuclear cells
isolated from spleens and brains/spinal cords of treated and control
mice were also analyzed using a cytometric bead array (CBA) kit and
ﬂow cytometer. No consistent differences in cytokine levels were seen
between treatment and control groups (Supplementary Figs. S3C–D).
Peptide-speciﬁc responses were most evident when analyzing IFNγ and
IL-17 from the mononuclear cells isolated from the brain and spinal
cords of both the control and anti-SEMA4D treated groups. Lastly, todetermine overall functional immunocompetence, clearance of an infec-
tiousmicroorganismwas assessed in the presence of high concentrations
of anti-SEMA4D antibody (Gleichmann et al., 1989). Viral clearance was
measured in inﬂuenza virus-infected rats that had received 5 weekly in-
travenous injections of varying doses of anti-SEMA4D antibody VX15/
2503 prior to virus infection and 3weekly doses subsequent to infection.
VX15/2503, at doses up to 200 mg/kg, did not impair or delay viral clear-
ance in this host resistance model (Supplementary Fig. S4). In aggregate,
these data indicate that the improvement in EAE clinical scores observed
in anti-SEMA4D treated cohorts is not due to overt suppression of im-
mune responses elicited against EAE-related myelin antigens.
In contrast to the limited effect of anti-SEMA4D antibody on lym-
phocytes and immune activity, a relatively dramatic inhibition of
microglial activation is observed as previously reported by Okuno
et al. (27). Spinal cord sections of SJL EAE mice induced by adoptive
transfer and treated with either anti-SEMA4D (MAb 67-2) or control
IgG (MAb 2B8) were examined for hematoxylin and eosin (H&E) histo-
chemistry and immunohistochemistry for macrophage/microglial
markers. H&E staining of representative sections from animals approx-
imating the group mean score in each cohort revealed clearly visible
areas of enhanced cellular densities suggestive of immune cell inﬁltra-
tion at sites of EAE lesions (Supplementary Figs. S5A–B). Immunohisto-
chemical analysis of macrophage/microglia using an anti-F4/80
antibody revealed signiﬁcantly greater staining within the spinal cords
of the control IgG cohort as compared to anti-SEMA4D-treated animals
(Supplementary Figs. S5C–D). Themajority of F4/80-positive cells were
CD45 low (data not shown), indicating that these cells were of
261E.S. Smith et al. / Neurobiology of Disease 73 (2015) 254–268microglial and not inﬁltrating macrophage origin. These results suggest
reduced activation and/or migration of microglial cells in animals treat-
ed with anti-SEMA4D antibody.
SEMA4D blockade restores blood–brain barrier integrity
It has been previously demonstrated that SEMA4D signaling through
the PLXNB1 receptor on endothelial cells induces cytoskeletal rear-
rangements, cellular activation and migration (Basile et al., 2004;
Conrotto et al., 2005). SEMA4D expressed on or released from activated
immune cells in neuroinﬂammatory disease may through these mecha-
nisms compromise the integrity and function of the blood–brain barrier
(BBB). The BBB is a highly complex brain endothelial structure of thedif-
ferentiated neurovascular system comprised of endothelial cells,
pericytes and astrocytes. BBB compromise has been implicated in a
number of neurodegenerative diseases, including meningitis, brain
edema, epilepsy, Alzheimer's disease (AD), Parkinson's disease (PD),
stroke, amyotrophic lateral sclerosis (ALS), and MS (reviewed by
(Zlokovic, 2011)).
To determine if anti-SEMA4D antibody administration during EAE
can protect BBB integrity in vivo, SJLmicewere sensitized by immuniza-
tion with PLP139–151/CFA, then treated weekly from day 7 post-
induction with either control IgG (MAb 2B8) or anti-SEMA4D (MAb
67-2). On day 13, during the acute phase of the disease, mice were
sacriﬁced and lumbar spinal cord samples were prepared for histopath-
ological analysis of ﬁbrinogen leakage from the microvasculature into
CNS interstitial tissue. EAE-related neuropathology was associated
with enhanced extravascular leakage of ﬁbrinogen serum protein in
lumbar spinal cords (Figs. 2A–C). Anti-SEMA4D antibody-treated EAE
mice exhibited greatly diminished ﬁbrinogen leakagewithin themicro-
vasculature, suggesting that BBB integrity is maintained or restored
when SEMA4D is neutralized during the acute phase of disease. Protec-
tion of the neurovascular unit and preservation of BBB integrity may
contribute to the therapeutic beneﬁt of anti-SEMA4D antibody in
neuroinﬂammatory and neurodegenerative disease.
To further analyze the impact of SEMA4DonBBB,we employed a pre-
viously described dynamic in vitro blood–brain barrier (DIV–BBB)model
(Cucullo et al., 2011). Brieﬂy, themodel consists of hollowpolypropylene
ﬁbers that contain transcapillary 2 to 4-μmdiameter pores. The ﬁbers are
connected to a pulsatile pump that facilitates continuous ﬂow of media,
cells, and experimental compounds through the ﬁbers. Human brain en-
dothelial cells are inoculated into the luminal compartment and allowed
to adhere to and coat the inside walls of the ﬁbers, while human astro-
cytes are seeded into the abluminal compartment bathing the outside
surface of the ﬁbers. The endothelial cells and astrocytes interact across
themembrane to induce formation of tight junctions between endothe-
lial cells, the integrity of which can be monitored continuously by mea-
surement of trans-endothelial electrical resistance (TEER). Introduction
of increasing concentrations of recombinant SEMA4D (rSEMA4D) into
the luminal compartment resulted in decreased TEER values reﬂecting
a breakdown of tight junctions between the cells. Introduction of a con-
trol recombinant protein had no impact (data not shown). The break-
down of BBB was reversed within 24 h by the addition of anti-SEMA4D
antibody (VX15/2503; Fig. 2D). Introduction of control IgG antibody
(MAb 2955) did not affect SEMA4D-induced BBB compromise.
To further investigate the mechanism of SEMA4D induced break-
down of BBB, primarymouse CNS endothelial cultures were established
in standard culture plates and were treated with rSEMA4D or with a
known BBB disruptor, tumor necrosis factor-alpha (TNFα). Immunocy-
tochemistry was ﬁrst performed to assess the subcellular localization
patterns of the key BBB tight junction protein, Claudin-5 (CLN-5). Un-
treated cultures exhibited the signature staining pattern for CLN-5 in
which the majority of signal was detected on membranes between ad-
jacent endothelial cells (Fig. 2E). Addition of the proinﬂammatory cyto-
kine TNFα (100 ng/ml for 12 h) resulted in a signiﬁcant loss of CLN-5, as
previously described (Fig. 2F; (Aslam et al., 2012)). Exposure torSEMA4D (100 ng/ml for 12 h) led to a similar dampening of
membrane-associated CLN-5 signal and a partially compensatory en-
hancement of intracellular compartment staining (Fig. 2G). Homoge-
nates generated from control, TNFα, and rSEMA4D-treated cells after
6 and 12 h of exposure were analyzed by SDS-PAGE and immunoblot-
ting to assess levels of CLN-5. Treatment with either TNFα or rSEMA4D
resulted in reduced CLN-5 levels beginning at 6 h and remaining low at
12 h (Figs. 2H and I). These data indicate that SEMA4D promotes break-
down of the BBB via a signaling cascade that involves transient down-
regulation of CLN-5 on endothelial cells, and that BBB integrity can be
restored by antibody neutralization of SEMA4D.
Anti-SEMA4D penetrates the CNS in the setting of EAE
Since T cells express the highest concentration of membrane
SEMA4D, we investigated the level of antibody saturation on T cells
within the CNS in EAE-induced SJL mice. T cells were isolated from
brains and spinal cords of EAE mice treated with anti-SEMA4D (VX15/
2503) or control IgG (MAb 2955). The results show that anti-SEMA4D
was bound to recovered T cells at saturation levels up to approximately
90% (Supplementary Figs. S6A–D). However, since T cells circulate and
may bind antibody in the periphery, it remained to be determined
whether anti-SEMA4D actually penetrates into the CNS in the setting
of EAE.
The presence of anti-SEMA4D (MAb 67-2) in cerebellar brain sec-
tions from EAE-induced DA rats was immunohistochemically detected
using a rat-adsorbed goat anti-mouse antibody (Supplementary Figs.
S6E–G). This antibody does not recognize rat IgG, but readily detects
the presence of mouse IgG (data not shown). Large areas of antibody
penetration into the brain were observed for MAb 67-2 as well as con-
trol IgG-treated EAE rats. This staining pattern was not detected in un-
treated naïve animals. The results demonstrate that antibody can
indeed penetrate into brain of EAE rats in antigen-independent fashion.
Effects of SEMA4D on oligodendrocyte precursor cells
Moreau-Fauvarque and colleagues demonstrated SEMA4D expres-
sion is up-regulated on oligodendrocytes after spinal cord lesion and
that SEMA4D acts as an inhibitor of axonal regeneration (Moreau-
Fauvarque et al., 2003). Giraudon et al. have reported that T cell-
derived SEMA4D affects immature neural cell survival and blocks pro-
cess extension (Giraudon et al., 2004). In the setting of stroke, Taniguchi
et al. reported that the number ofmature oligodendrocytes signiﬁcantly
increases in the brains of both non-ischemic and post-ischemic
SEMA4D-deﬁcient mice as compared to wild-type mice (Taniguchi
et al., 2009). These reports indicate that SEMA4D signaling is involved
in oligodendrocyte development and can play an important role in re-
covery from CNS injury.
To assess the effects of SEMA4D on the oligodendrocyte lineage and
the ability of anti-SEMA4D antibody to promote survival and
differentiation of oligodendrocyte precursor cells (OPC), we established
OPC cultures and analyzed three physiologic processes central to oligo-
dendrocyte function and viability: actin ﬁlament structure, apoptosis,
and differentiation. Exposure of OPC cultures to recombinant SEMA4D
led to amarked rearrangement in actin ﬁlament organization indicative
of cytoskeletal collapse, while addition of anti-SEMA4D prevented this
cytoskeletal effect (Figs. 3A–D). In companion cultures, recombinant
SEMA4D exposure resulted in higher percentages of caspase-3 positive
apoptotic cells after 4 days (Fig. 3E) and fewer OPC differentiating into
mature MBP-expressing oligodendrocytes after 8 days (Fig. 3F). In
each assay, anti-SEMA4D antibody, but not control IgG, reversed these
effects to levels similar to BSA-treated negative controls. These in vitro
results support previous reports describing a role for SEMA4D signaling
in multiple mechanisms central to oligodendrocyte function and
viability.
Fig. 2. SEMA4D inhibition preserves integrity of blood–brain barrier. Mice (12 week-old SJL/J; N= 10/group)were sensitizedwith PLP139–151/CFA, then treated once perweek from day 7
post-inductionwith 30 mg/kg control IgG (MAb 2B8; A) or anti-SEMA4D (MAb 67-2; B). On day 13, during the acute phase of the disease, 4 representativemice per groupwere sacriﬁced
and lumbar spinal cord were analyzed by immunohistochemical staining of ﬁbrinogen, a serummarker of extravascular leakage (A–C). Clinical disease in mice in the control IgG-treated
cohort reached a mean disease score of 2.25, while in the anti-SEMA4D-treated group the mean score was 0.75. Scale bars depicted in A and B indicate 50 μm. Statistical signiﬁcance was
determined by Student's t-test where “**”=p b 0.01 and “***”=p b 0.001. The effect of SEMA4D on BBB integrity was subsequently examined in a previously described dynamic in vitro
blood–brain barrier (DIV–BBB) model (17). The integrity of the barrier was monitored continuously over the course of the experiment by measurement of transendothelial electrical re-
sistance (TEER; D). At peak TEER (approximately 14 days in vitro), 0.5, 5, and 50 μg/ml recombinant SEMA4D was added successively at 12-h intervals. At 36 h after initial SEMA4D ex-
posure, control IgG (MAb2955; 1 DIV–BBB unit) or anti-SEMA4D (VX15/2503; 2 DIV–BBB units)was added and TEERmeasured for another 132h. Error bars represent standarddeviation.
The data shown are representative of 3 independent experiments. To assess effects of SEMA4D on tight junction protein Claudin-5 (CLN-5), primarymouse CNS endothelial cultureswere
left untreated (E) or incubatedwith 100 ng/ml TNFα as a positive control (F) or recombinant SEMA4D(G) for 12 h, thenprocessed forﬂuorescence immunocytochemistry (E-G), or treated
for 6 or 12 h and subjected to SDS-PAGE and immunoblotting for 22-kDa Claudin-5 and 42-kDaβ-actin loading control (H). Gel imageswere scanned and subjected to densitometry using
ImageJ software (I). Error bars indicate standard error. These data are representative of 3 independent experiments.
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Fig. 3. Anti-SEMA4D rescues oligodendrocyte precursor cells (OPC) from SEMA4D-induced cytoskeletal collapse, apoptosis and inhibition of differentiation. Oligodendrocyte precursor
cells (OPCs) were established from dissociated spinal cord or cortices of P2 rat pups. OPCs were seeded for a collapse assay and subsequently treated with control protein (C35 (Evans
et al., 2006); A), 50 μg/ml recombinant SEMA4D alone (B), 50 μg/ml SEMA4D + 500 μg/ml control IgG (MAb 2955; C), or 50 μg/ml SEMA4D + 500 μg/ml anti-SEMA4D antibody
(VX15/2503; D). Cells were ﬁxed with 4% PFA and cytoskeletal changes were visualized by Phalloidin-A488 staining. Scale bar in D represents 50 μm. For the differentiation assay,
OPCs were plated onto wells coated with poly-L-lysine (PLL; 10 μg/ml) + BSA (50 μg/ml), PLL (10 μg/ml) + SEMA4D (50 μg/ml), PLL (10 μg/ml) + SEMA4D (50 μg/ml) + control IgG
(MAb2955; 250 μg/ml), or PLL (10 μg/ml)+ SEMA4D (50 mg/ml)+ anti-SEMA4D (VX15/2503; 250 μg/ml). (E) Cells were cultured for 4 days and then ﬁxedwith 4% PFA and processed
for immunohistochemistry to assess extent of apoptosis via enumeration of activated caspase 3-positive cells. (F) Companion cultureswere established under an identical set of treatment
conditions for 8 days, at which time cells were ﬁxedwith 4% PFA and processed for immunohistochemistry to assess number of cells expressing the mature oligodendrocyte marker, my-
elin basic protein (MBP). Error bars represent standard deviation. Statistical signiﬁcancewas determined byANOVAwith Bonferroni'sMultiple Comparison Testwhere “**”=p b 0.05 and
“****”= p b 0.001.
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To examine the impact of anti-SEMA4D in vivo on myelin in
antibody-treated EAE animals, we assessed spinal cord myelination sta-
tus by toluidine blue histochemistry and myelin structural integrity by
transmission electron microscopy (TEM). Naïve rats or rats induced to
develop EAE and treated with control IgG or anti-SEMA4D were
sacriﬁced and processed for toluidine blue staining or TEM during the
chronic phase of disease at day 35 post-recombinant MOG1–125/CFA im-
munization. A series of toluidine blue-stained spinal cord cross-sections
at the level of L1 of the dorsal column substructure were assessed for
total myelin content by quantitative image analysis. EAE rats that re-
ceived anti-SEMA4D (MAb 67-2) harbored signiﬁcantly more myelinat-
ed axons in the dorsal funicular space than those administered control
IgG (MAb 2B8; Figs. 4A–E). Areas of EAE-induced demyelination and sig-
niﬁcant immune cell inﬁltrationwere readily apparent in the control IgG-
treated EAE cohort (Fig. 4C) and occurred at a higher frequency than in
anti-SEMA4D treated EAE rats (Fig. 4D). As shown in Fig. 4E, there is ahighly signiﬁcant difference in percentage of myelin loss in control IgG-
treated EAE rats as compared to naïve control animals. Myelination
values observed for anti-SEMA4D-treated EAE rats were, in contrast, sta-
tistically indistinguishable from those of naïve rats. Examination of dorsal
column axons and optic nerve by TEM conﬁrmed the toluidine blue ob-
servations and revealed signiﬁcant differences in myelinated axon
ultra-structure between control IgG- (Figs. 4F and I) and anti-SEMA4D-
treated EAE animals (Figs. 4G and J), with the latter showing greatly en-
hancedmyelin integrity similar to that observed in naïve control animals
(Figs. 4H andK). These results suggest that, in addition tomaintaining the
integrity of the BBB, anti-SEMA4D antibody directly protects myelin in a
neuroinﬂammatory/neurodegenerative disease.
Anti-SEMA4D treatment enhancesmyelin repair in lysolecithin-lesioned rats
Lysophosphatidylcholine (LPC; lysolecithin), when stereotactically
injected into rat spinal cord, induces demyelinated lesions that undergo
a well-characterized process of endogenous remyelination (Pavelko
Fig. 4. Protection fromEAE-associated demyelination in vivo. To determine the effects of anti-SEMA4D antibody treatment onmyelination status, toluidine blue stainingwas performed on
coronal spinal cord sections fromnaïve rats and antibody-treated, EAE-induced DA rats. Animals received control IgG (MAb 2B8) or anti-SEMA4D (MAb67-2) 2×/week up to peak disease
starting on day 3 post-MOG immunization, then received antibodies 1×/week thereafter. On day 35, mice were sacriﬁced and processed for toluidine blue histochemistry. Area of
myelination (N= 4/group, representative of groupmean score) was quantiﬁed within the dorsal funiculus (outlined in green; A) for naïve (B), control IgG (C) and anti-SEMA4D-treated
rats (D), and represented as %myelin loss (E). Error bars represent standarddeviation and “****” indicates p b 0.0001 as determined byANOVA. Scale bar in A equals 500 μm,while those in
B–D equal 50 μm. Coronal spinal cord (F–H) and optic nerve sections (I–K) from control IgG (F, I) anti-SEMA4D-treated rats (G, J), and naïve rats (H, K) were also processed for transmis-
sion electron microscopy. Scale bar in K represents 5 μm.
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cyte precursor cell differentiation and viability in the presence of recom-
binant SEMA4D in vitro and improves myelin proﬁles in MAb 67-2
treated EAE rats, we assessed the ability of anti-SEMA4D to enhance
remyelination in this timed lesion model, which is not dependent
upon peripheral activation of the immune system or signiﬁcant BBB
compromise.. LPC was stereotactically infused into the dorsal funiculus
of Sprague–Dawley rat spinal cords, followed 2 days later by implanta-
tion of Alzet osmotic pumps that delivered either control IgG or anti-
SEMA4D starting on day 3 (90 μg/day; Fig. 5A). Sham control rats
were injected with saline instead of LPC and underwent implantation
with Alzet pumps that infused control IgG. Onday 14 after LPC injection,
rats were sacriﬁced. Spinal columns were removed, lesions imaged by
ex vivo magnetic resonance imaging (MRI; Figs. 5B and C), and spinal
cord tissue analyzed by TEM and immunohistochemistry. Rats treated
with anti-SEMA4D harbored lesions that trended smaller in overall vol-
ume (P = 0.08; Fig. 5D) and whose MRI-based pixel proﬁles revealed
evidence of diminished severity as compared to control IgG-treated an-
imals (Fig. 5E). Analysis of the outer edge of the lysolecithin lesion usingTEM revealed that within the margin of the lesion the anti-SEMA4D
treated group harbored more axons with thin myelin in proportion to
their axon diameter than rats receiving control IgG infusion (Figs. 5F–
H). The G-ratio is the numerical ratio between the diameter of the
axon proper and the outer diameter of the myelinated ﬁber. An in-
creased G-ratio is a distinguishing characteristic of remyelinated
axons. Anti-SEMA4D treatment had a dramatic effect on microglial
activation and migration of oligodendrocyte precursor cells at the site
of lesions as determined by co-immunohistochemistry for Iba1 (for ac-
tivated microglia; Figs. 6A–C) and Nkx2.2 (for pre-myelinating oligo-
dendrocytes; Figs. 6D–F). Sharply reduced staining for Iba1 indicates
reduced activation of inﬂammatory microglia at the site of lesions as
also seen in anti-SEMA4D treated EAE mice (Supplementary Fig. S5)
and as previously reported by Okuno et al. (27). Importantly, anti-
SEMA4D treatment led to signiﬁcantly increased numbers of Nkx2.2-
positive cells within the lesioned dorsal funiculus (Fig. 6G). Strikingly,
there appears to be a redistribution and a concentration of Nkx2.2 pos-
itive cells centered in the region of the lesion in sections from anti-
SEMA4D treated animals (compare distribution of Nkx2.2 positive
Fig. 5. Anti-SEMA4D delivery improves endogenous remyelination in a lysolecithin-lesioned rat spinal cord. Lysophosphatidylcholine (LPC; lysolecithin) was stereotactically infused into
the dorsal funiculus of Sprague–Dawley rat spinal cords (N= 12/group), followed 2 days later by implantation of Alzet osmotic pumps that delivered either control IgG or anti-SEMA4D
(90 μg/day; study design schematic shown in A). Sham control rats were injected with saline and underwent implantation with Alzet pumps that infused control IgG (N= 6/group). On
day 14 after LPC injection, rats were sacriﬁced and perfusedwith 4% glutaraldehyde or 4% paraformaldehyde in saline. Spinal columnswere removed, and lesions imaged via ex vivomag-
netic resonance imaging (MRI; B and C), and spinal cord tissue analyzed by electron microscopy and immunohistochemistry. Using the MRI imaging data, lesion volumes (D) and pixel
intensity proﬁles (E) were calculated for each rat. Transmission electron microscopy was performed on spinal cord tissue from control IgG (F), anti-SEMA4D (G), and sham operated
(H) rats. Scale bars in F–H equal 1 μm. Arrows in F depict demyelinated axons, while asterisks in G demarcate remyelinated axons. Error bars represent standard error and statistical sig-
niﬁcance was determined using ANOVA.
Fig. 6. SEMA4D blockade preventsmicroglial activation and leads to concentration of Nkx2.2+ oligodendrocytes in region of LPC-induced lesion. To determine if anti-SEMA4D treatment
affected the oligodendrocyte lineage in vivo, co-immunohistochemistry for Iba1 (for activatedmicroglia; A–C) and Nkx2.2 (for pre-myelinating oligodendrocytes; D–F) was performed on
spinal cord tissue from control IgG (A, D), anti-SEMA4D (B, E), and sham operated (C, F) rats. Numbers of Nkx2.2-positive cells within the dorsal funiculus were calculated (G). Error bars
represent standard error and statistical signiﬁcance was determined using ANOVA, where “*” indicates p = 0.05.
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motesmyelin repair in amodel of chemically induced demyelination by
mechanisms that result in inducing migration of OPC to the area of le-
sion or altering the balance of proliferation and apoptosis of Nkx2.2 pos-
itive pre-myelinating oligodendrocytes in the region of the lesion.
Further investigation will be required to determine whether interac-
tions between activated microglia and OPC play a role in such
redistribution.Discussion
SEMA4D plays a role inmultiple cellular processes that contribute to
pathophysiology of neuroinﬂammatory/neurodegenerative diseases
and is, therefore, a unique target for therapeutic development. Ourﬁnd-
ings reported here indicate that anti-SEMA4D antibody may provide
therapeutic beneﬁt in the setting of a neuroinﬂammatory and neurode-
generative disease such as MS via at least two non-mutually exclusive
mechanisms: First, anti-SEMA4D prevents SEMA4D-mediated BBB dis-
ruption at the level of themicrovasculature to impede peripheral cell in-
ﬁltration and otherwise prevent compromise to the neurovascular unit.
Second, anti-SEMA4D prevents the inhibition of migration, survival and
differentiation of oligodendrocyte precursor cells and their myelinating
function by SEMA4D.
Dysregulated migration of lymphocytes and transendothelial move-
ment of macromolecules across an altered BBB are prominent features
of many neuroinﬂammatory and neurodegenerative disorders, includ-
ing Alzheimer's disease, Parkinson's disease (PD), stroke, amyotrophic
lateral sclerosis (ALS), and MS. The effect of SEMA4D on BBB integrity
and the protection afforded by anti-SEMA4D antibody in the setting of
EAE are novel ﬁndings. SEMA4D signaling through the PLXNB1 receptor
has been shown previously to induce cytoskeletal rearrangements and
activation and migration of endothelial cells (Basile et al., 2005; Yang
et al., 2011). We demonstrated in the DIV–BBB model that SEMA4D
can disrupt the integrity of an artiﬁcial BBB, and that administration of
anti-SEMA4D in either this model or in vivo in EAE can reverse and/or
prevent SEMA4D-mediated BBB disruption (Fig. 2). This effect is medi-
ated, at least in part, by preventing SEMA4D-induced changes to the ex-
pression or localization of a key tight junction protein, CLN-5. Further
experimentation will be needed to ﬁnely detail how SEMA4D signaling
affects tight junction protein expression and/or subcellular localization
in brain microvascular endothelial cells.
Over the course of MS-related disease, there is extensive demyelin-
ation that is associated with marked destruction and loss of cells com-
prising the oligodendrocyte lineage (Ozawa et al., 1994). Endogenous
remyelination mechanisms fail during the recovery phase in part be-
cause of oligodendrocyte death as well as the inability of OPCs to mi-
grate and differentiate into mature myelinating oligodendrocytes
(Wolswijk, 2000). Data obtained from other experimentally induced
demyelination models indicate that newly maturing OPCs, in contrast
to surviving mature oligodendrocytes, are required for remyelination
during the recovery phase (Levine andReynolds, 1999). Our results con-
ﬁrm those reported by others (Giraudon et al., 2004) of the deleterious
effects of SEMA4D signaling on the viability and differentiation capabil-
ity of OPCs (Fig. 3). After a demyelinating insult, homeodomain tran-
scription factor Nkx2.2 expression has been shown by Watanabe et al.
to initially appear in NG2-expressing OPCs surrounding a lesion
in vivo and subsequently in both precursors and oligodendrocyteswith-
in the lesion prior to the onset of remyelination (Watanabe et al., 2004).
Interestingly, intrathecal anti-SEMA4D administration in the timed ly-
solecithin model led to increased numbers of Nkx2.2-positive cells
proximal to the spinal cord lesion (Fig. 6), suggesting that this enhanced
migration and concentration of precursors may underlie the improved
remyelination observed in this study. It is, however, not clear whether
this SEMA4D-mediated activity is a direct effect of SEMA4D expressed
on Nkx2.2-positive OPC (Supplementary Fig. S2) or an indirect resultof SEMA4D signaling through Plexin-B1 receptor positive CNS-
resident glial cells.
Many of the currently available MS therapies are based upon
targeted immunosuppression as a means to prevent autoreactive T
cells from entering the CNS and further damaging axon-envelopingmy-
elin sheaths. SEMA4D is highly expressed on cells of the immune system
and it was possible that antibody-based inhibition of SEMA4D would
lead to measurable immune suppression. Indeed, experiments in
SEMA4D-deﬁcient (SEMA4D knockout) mice demonstrated reduced
antibody responses to T cell-dependent antigens and impaired T cell
priming. Both of these functions were restored by administration of ex-
ogenous SEMA4D (Shi et al., 2000). Moreover, SEMA4D knockout mice
were resistant to the development of EAE due at least in part to a re-
duced immune response to the EAE-inducing antigen (Kumanogoh
et al., 2002). There are, of course, important differences between genetic
ablation in a SEMA4D knock-out mouse and anti-SEMA4D treatment in
an adult animal with a mature and normal immune system. While we
have detected limited effects of anti-SEMA4D antibody on germinal
center morphology in repeat dosing studies (data not shown), adminis-
tration of anti-SEMA4D antibody did not lead to suppression of T cell
and cytokine responses to the EAE-inducing peptide (Supplementary
Fig. S3) or impede immune clearance of inﬂuenza virus infection (Sup-
plementary Fig. S4). Moreover, anti-SEMA4D antibody ameliorates dis-
ease in an adoptive transfer model in which myelin-speciﬁc T cells are
pre-activated in vitro (Fig. 1B) and also improves remyelination status
in the lysolecithin model of direct chemically-induced demyelination
(Fig. 5). These observations indicate that mechanisms of action other
than general immunosuppression are responsible for the clinical beneﬁt
observed in anti-SEMA4D antibody-treated EAE animals.
Despite the pleiotropic effects of SEMA4D on BBB integrity, neuronal
process extension, and oligodendrocyte differentiation/viability, we did
not detect any drug-related side effects/toxicities of anti-SEMA4D anti-
body in any of our in vivo repeat-dosing studies. Moreover, single and
repeat dose toxicity, pharmacokinetic, and pharmacodynamic studies
with a humanized anti-SEMA4D (VX15/2503) antibody in cynomolgus
monkeys and rats have been completed, with no toxicity observed
(manuscript in preparation). Currently, there are 9 FDA-approved,
disease-modifying medications for the treatment of MSwith purported
mechanisms, where deﬁned, mostly related to either impeding T cell
trafﬁc to the CNS or inhibiting inﬂammatory responses. The unique fea-
ture of anti-SEMA4D therapy is that it combines independent mecha-
nisms of action that overlap with the anti-inﬂammatory effects of
several of these clinical agents and further extends activity to restoring
and protecting the integrity of both BBB and myelinated axons. While
approved immunosuppressive and anti-inﬂammatory drugs have
been shown to be effective in transiently suppressingMS-related symp-
toms and relapse frequency, many have signiﬁcant side-effects with
varying degrees of severity (Weber et al., 2012). In animal studies and
ongoing phase 1 clinical trials to date, anti-SEMA4D antibody adminis-
tration has not been associated with signiﬁcant overt toxicity.
We have demonstrated that anti-SEMA4Dantibody acts throughmul-
tiplemechanisms to ameliorate a neuroinﬂammatory/neurodegenerative
disease process. Our results show that peripherally administered anti-
SEMA4D antibody is active within the CNS in the setting of a severely
compromised BBB in EAE. In a separate study to be reported elsewhere
(A. Southwell, M. Hayden et al., submitted for publication), we conﬁrm
striking protection of both gray and white matter in a transgenic
Huntington’s diseasemodel, a disease settingwithmuchmore limited in-
ﬂammation or compromise to BBB. This may be relevant to treatment of
progressive forms ofMSwhich, although they exhibit endothelial cell ab-
normalities within CNS vasculature, do not show evidence of BBB com-
promise that is as severe or extensive as that observed in relapsing
forms of the disease (Soon et al., 2007; Leech et al., 2007). In summary,
wehave developed an antibody-based therapeutic to inhibit SEMA4D sig-
naling as a novel strategy to treat neuroinﬂammatory/neurodegenerative
diseases. The drug target, semaphorin 4D, participates inmultiple cellular
267E.S. Smith et al. / Neurobiology of Disease 73 (2015) 254–268processes, including BBB integrity,microglial activation, and oligodendro-
cyte function, which are known to contribute to the pathophysiology of a
number of debilitating neuroinﬂammatory and neurodegenerative
diseases.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2014.10.008.
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